First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
So who else could be interested in the oestrogen degrader?
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
The recently unveiled conjugate DS3610a is to start phase 1.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
After menin, the company tries again with farnesyl transferase.
The companies clash over survival curve similarities – and differences.